JP2010506926A5 - - Google Patents

Download PDF

Info

Publication number
JP2010506926A5
JP2010506926A5 JP2009533371A JP2009533371A JP2010506926A5 JP 2010506926 A5 JP2010506926 A5 JP 2010506926A5 JP 2009533371 A JP2009533371 A JP 2009533371A JP 2009533371 A JP2009533371 A JP 2009533371A JP 2010506926 A5 JP2010506926 A5 JP 2010506926A5
Authority
JP
Japan
Prior art keywords
mhc class
pharmaceutical formulation
residue
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009533371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506926A (ja
Filing date
Publication date
Priority claimed from US11/582,596 external-priority patent/US20080095798A1/en
Application filed filed Critical
Publication of JP2010506926A publication Critical patent/JP2010506926A/ja
Publication of JP2010506926A5 publication Critical patent/JP2010506926A5/ja
Pending legal-status Critical Current

Links

JP2009533371A 2006-10-18 2007-10-18 Ｉｉ−Ｋｅｙ増強ワクチンの効力 Pending JP2010506926A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/582,596 US20080095798A1 (en) 2006-10-18 2006-10-18 Ii-key enhanced vaccine potency
PCT/US2007/022230 WO2008060385A2 (en) 2006-10-18 2007-10-18 Li-key enhanced vaccine potency

Publications (2)

Publication Number Publication Date
JP2010506926A JP2010506926A (ja) 2010-03-04
JP2010506926A5 true JP2010506926A5 (enExample) 2010-11-25

Family

ID=39318185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533371A Pending JP2010506926A (ja) 2006-10-18 2007-10-18 Ｉｉ−Ｋｅｙ増強ワクチンの効力

Country Status (5)

Country Link
US (1) US20080095798A1 (enExample)
EP (1) EP2081591A4 (enExample)
JP (1) JP2010506926A (enExample)
CA (1) CA2666342A1 (enExample)
WO (1) WO2008060385A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
AU2008211199A1 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
US8957031B2 (en) * 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
CA2730773A1 (en) 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
CA2736842A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
CA2731444A1 (en) * 2008-09-02 2010-03-11 Antigen Express, Inc. Human papillomavirus / li-key hybrids and methods of use
CN102292102A (zh) 2008-11-21 2011-12-21 哥本哈根大学 免疫应答的引发
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
WO1997049430A1 (en) * 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
WO2004030616A2 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Similar Documents

Publication Publication Date Title
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
JP2010506926A5 (enExample)
Lo et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
JP2006527762A5 (enExample)
JP2008530245A5 (enExample)
TR201908199T4 (tr) HPV'ye karşı aşılar.
JP2016516723A5 (enExample)
JP2008529558A5 (enExample)
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
WO2009073330A3 (en) Novel vaccines against multiple subtypes of influenza virus
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
JP2013518052A5 (enExample)
JP2014523878A5 (enExample)
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
Cossette et al. Intranasal subunit vaccination strategies employing nanomaterials and biomaterials
WO2008060385A3 (en) Li-key enhanced vaccine potency
ATE465753T1 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
Zhao et al. Adjuvant-free, self− assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses
JP2016514672A5 (enExample)
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
Desheva et al. Mast cell degranulation and histamine release during A/H5N1 influenza infection in influenza-sensitized mice
RU2018103757A (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
JP2013516469A5 (enExample)
JP2012501351A5 (enExample)